KITOV PHARMA LT / S (KTOV) should post earnings of – $ 0.01 per share



[ad_1]

  KITOV PHARMA LT / S logo KITOV PHARMA LT / S (NASDAQ: KTOV) Announce Earnings Per Share of ($ 0.01) According to Zacks Investment Research, Zero badysts have provided earnings estimates for KITOV PHARMA LT / S. The company is expected to announce its next quarterly earnings report on Monday, January 1.

Analysts expect KITOV PHARMA LT / S to report earnings per share of $ 0.03 per share. action for the current fiscal year and provides that the company will post a profit of ($ 0.02) per share next year .The average shares are an average based on a survey of badysts KITOV PHARMA LT / S.

A number of brokerages recently commented on KTOV HC Wainwright re-evaluated the "buy" rating and set a target price of $ 13.00 on KITOV PHARMA LT / S in a report on Wednesday, June 6. LuEngine noted the actions of KITOV P HARMA LT / S from a "sell" rating to a "hold" rating in a report on Wednesday, May 2nd. Finally, Zacks Investment Research cut KITOV PHARMA LT / S shares from a "hold" rating to a "sell" rating in a report on Saturday, June 9.

KTOV shares fell by $ 0.01 at midday Friday, reaching $ 2.20. 168 shares of the company were exchanged for an average volume of 169,340. KITOV PHARMA LT / S has a 12-month low of $ 1.55 and a 12-month high of $ 3.81. The stock has a market capitalization of $ 25.22 million, a capitalization ratio of -1.69 and a beta of 2.88.

KITOV PHARMA LT / S Presentation of the Company

Kitov Pharma Ltd, through its subsidiaries, is a biopharmaceutical company in the development phase in Israel. He develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. KIT-302, the company's flagship drug, is a fixed-dose combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study

Feature article: Earnings per share (PSE)

Get a free copy of Zacks' research report on KITOV PHARMA LT / S (KTOV)

For more information about the offers of Zacks Investment Research, visit Zacks.com



News and Comments for KITOV PHARMA LT / S Daily – Enter your email address below to receive a daily concise summary of the latest news and notes badysts for KITOV PHARMA LT / S and affiliates with MarketBeat.com's free daily newsletter

[ad_2]
Source link